This question was asked during Session 2 of the Mastering IMHA program:
Question: Do these advanced therapies you've discussed require dosing adjustments in chronic kidney disease patients?
Answer (provided by John Loftus, PhD, DVM, DACVIM (SAIM, Nutrition)):
Most of these drugs undergo hepatic metabolism so I generally wouldn’t. I do try to check to see if there is any need to dose reduce but the evidence in small animals is fairly sparse so we’re often extrapolating from people.
